Back to Authors

Tu, Pang‐Hsien

https://orcid.org/0000-0003-2821-7335

Mayo Clinic

Institute of Biomedical Sciences, Academia Sinica

Citations 2

Nuclear translocation of AMPK-α1 potentiates striatal neurodegeneration in Huntington’s disease
Ju, Tz‐Chuen , Lin, Jiun‐Tsai, Chang, Ching‐Pang , Chang, Wei-Cheng, Kang, Jheng-Jie, Sun, Cheng‐Pu , Tao, Mi‐Hua , Tu, Pang‐Hsien , Chang, Chen , Dickson, Dennis W. , Chern, Yijuang , Chen, Huimei , Dickson, Dennis W

Journal of Cell Biology | July 18, 2011 | Volume: 194 | Issue: 2 | Pages: 209-227

10.1083/jcb.201105010 Get It

Adenosine monophosphate–activated protein kinase (AMPK) is a major energy sensor that maintains cellular energy homeostasis. Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of CAG repeats in the huntingtin (Htt) gene. In this paper, we report that activation of the α1 isoform of AMPK (AMPK-α1) occurred in striatal neurons of humans and mice with HD. Overactivation of AMPK in the striatum caused brain atrophy, facilitated neuronal loss, and increased formation of Htt aggregates in a transgenic mouse model (R6/2) of HD. Such nuclear accumulation of AMPK-α1 was activity dependent. Prevention of nuclear translocation or inactivation of AMPK-α1 ameliorated cell death and down-regulation of Bcl2 caused by mutant Htt (mHtt). Conversely, enhanced expression of Bcl2 protected striatal cells from the toxicity evoked by mHtt and AMPK overactivation. These data demonstrate that aberrant activation of AMPK-α1 in the nuclei of striatal cells represents a new toxic pathway induced by mHtt.
Clinicopathologic and Genetic Profile of Intracranial Marginal Zone Lymphoma: A Primary Low-Grade CNS Lymphoma That Mimics Meningioma
Judkins, Alexander R. , Schwalb, Jason M. , Yachnis, Anthony T. , Burger, Peter C. , Scheithauer, Bernd W., Perry, Arie , Tu, Pang‐Hsien , Giannini, Caterina , Burack, Richard , O’Neill, Brian Patrick , Perry, Arie

Journal of Clinical Oncology | July 12, 2005 | Volume: 23 | Issue: 24 | Pages: 5718-5727

10.1200/jco.2005.17.624 Get It

PurposeAlthough rare overall, marginal zone B-cell lymphoma (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature. The aim of this study is to elucidate the biology and genetic features of this unusual tumor.Patients and MethodsFifteen CNS MZBCLs were studied clinically, pathologically, and genetically, including fluorescent in situ hybridization analyses with commercially available MALT1 and IgH break-apart and centromere 3, 7, 12, and 18 probes.ResultsCNS MZBCLs preferentially affect middle-aged women (female-to-male ratio, 4:1), with 93% presenting as dural-based masses mimicking meningioma. Ten patients with 1 to 7.6 years of follow-up after diagnosis showed no evidence of disease after radiation and/or chemotherapy. Like MZBCLs outside of the CNS, they consisted of CD20+, CD3−small B lymphocytes with varying degrees of plasmacytic differentiation and predominantly κ light-chain restriction (78%). Lymphoid follicles with follicular colonization were seen in three patients and deposition of amyloid was noted in samples from two patients, one of which was tumefactive. Neither Bcl-6 protein nor Epstein-Barr virus–encoded RNA was expressed. Trisomy 3 was detected in six of 12 patients, with no rearrangements of MALT1 or IgH and no trisomies of 7, 12, or 18 detected.ConclusionOur data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass. Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality that may contribute to the pathogenesis of this CNS lymphoma.